InfuSystem Holdings Q3 2024 Revenue Hits $45.3M

TL;DR

**InfuSystem Holdings Q3 Revenue: $45.3M YTD. Fiscal year ends Dec 31.**

AI Summary

InfuSystem Holdings, Inc. reported its Q3 2024 results, with total revenue for the nine months ending September 30, 2024, reaching $45.3 million. The company's fiscal year ends on December 31st. This filing covers the period up to September 30, 2024.

Why It Matters

This 10-Q filing provides investors with a quarterly update on InfuSystem's financial performance, including revenue figures, which are crucial for assessing the company's growth and profitability.

Risk Assessment

Risk Level: medium — The company's financial performance and market position are subject to the inherent risks of the medical device industry, including regulatory changes and competition.

Key Numbers

• $45.3M — Revenue (YTD) (Represents the total revenue for the nine months ending September 30, 2024.)
• 2024-09-30 — Reporting Period End Date (The end date of the fiscal quarter and nine-month period covered by this 10-Q filing.)
• 2024-11-08 — Filing Date (The date on which this 10-Q filing was submitted to the SEC.)

Key Players & Entities

• InfuSystem Holdings, Inc. (company) — Filer of the 10-Q report
• 20240930 (date) — End of the reporting period for the 10-Q
• $45.3 million (dollar_amount) — Total revenue for the nine months ending September 30, 2024
• 20241108 (date) — Filing date of the 10-Q

FAQ

Key Financial Figures

• $0.0001 — ich Registered Common Stock, par value $0.0001 per share INFU NYSE American LLC Indi

Filing Documents

• infu-20240930.htm (10-Q) — 1359KB
• infu-20240930xexx311.htm (EX-31.1) — 8KB
• infu-20240930xexx312.htm (EX-31.2) — 8KB
• infu-20240930xexx321.htm (EX-32.1) — 4KB
• infu-20240930xexx322.htm (EX-32.2) — 4KB
• infu-20240930_g1.jpg (GRAPHIC) — 760KB
• 0001628280-24-046739.txt ( ) — 10150KB
• infu-20240930.xsd (EX-101.SCH) — 52KB
• infu-20240930_cal.xml (EX-101.CAL) — 97KB
• infu-20240930_def.xml (EX-101.DEF) — 218KB
• infu-20240930_lab.xml (EX-101.LAB) — 639KB
• infu-20240930_pre.xml (EX-101.PRE) — 449KB
• infu-20240930_htm.xml (XML) — 1640KB

Financial Statements

Financial Statements 3 -Unaudited Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 3 -Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2024 and 2023 4 -Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 5 -Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 6 -Notes to the Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 3. Defaults Upon Senior Securities 36 Item 4. Mine Safety Disclosures 36 Item 5. Other Information 36 Item 6. Exhibits 38

Signatures

Signatures 39 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of ( in thousands, except par value and share data ) September 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 380 $ 231 Accounts receivable, net 22,761 19,830 Inventories, net 6,700 6,402 Other current assets 3,772 4,157 Total current assets 33,613 30,620 Medical equipment for sale or rental 4,699 3,049 Medical equipment in rental service, net of accumulated depreciation 37,001 34,928 Property & equipment, net of accumulated depreciation 3,910 4,321 Goodwill 3,710 3,710 Intangible assets, net 6,704 7,446 Operating lease right of use assets 5,735 6,703 Deferred income taxes 7,815 9,115 Derivative financial instruments 1,107 1,442 Other assets 1,009 1,581 Total assets $ 105,303 $ 102,915 LIABILITIES AND STOCKHOLDERS ' EQUITY Current liabilities: Accounts payable $ 8,908 $ 8,009 Other current liabilities 8,028 7,704 Total current liabilities 16,936 15,713 Long-term debt, net of current portion 27,975 29,101 Operating lease liabilities, net of current portion 4,879 5,799 Total liabilities 49,790 50,613 Stockholders' equity: Preferred stock, $ 0.0001 par value: authorized 1,000,000 shares; none issued — — Common stock, $ 0.0001 par value: authorized 200,000,000 shares; 21,234,303 shares issued and outstanding as of September 30, 2024 and 21,196,851 shares issued and outstanding as of December 31, 2023 2 2 Additional paid-in capital 112,869 109,837 Accumulated other comprehensive income 836 1,088 Retained deficit ( 58,194 ) ( 58,625 ) Total stockholders' equity 55,513 52,302 Total liabilities and stockholders' equity $ 105,303 $ 102,915 See accompanying notes to unaudited condensed consolidated financial statements. 3 Table of Contents INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDI

View Full Filing

View this 10-Q filing on SEC EDGAR